Recurrent Melanoma Clinical Trials

112 clinical trials for Recurrent Melanoma across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study — RECRUITING · PHASE2
• MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma — RECRUITING · PHASE1
• Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel) — RECRUITING · PHASE1
• Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery — ACTIVE_NOT_RECRUITING · PHASE3
• Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma — ACTIVE_NOT_RECRUITING · PHASE3
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) — ACTIVE_NOT_RECRUITING · PHASE2
• Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery — ACTIVE_NOT_RECRUITING · PHASE2
• Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery — COMPLETED · PHASE2
• Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial — ACTIVE_NOT_RECRUITING · PHASE2
• Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery — COMPLETED · PHASE3
• Dinaciclib in Treating Patients With Stage IV Melanoma — ACTIVE_NOT_RECRUITING · PHASE2
• Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV — ACTIVE_NOT_RECRUITING · PHASE1
• Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma — ACTIVE_NOT_RECRUITING · PHASE2
• Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma — ACTIVE_NOT_RECRUITING · PHASE1
• Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung — WITHDRAWN · PHASE1
• Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma — COMPLETED · PHASE1
• Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases — WITHDRAWN · PHASE1
• Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction — COMPLETED · PHASE1
• RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer — TERMINATED · PHASE1
• Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors — COMPLETED · PHASE1
• Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma — COMPLETED · PHASE2
• Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma — COMPLETED · PHASE2
• Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma — COMPLETED · PHASE2
• flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer — COMPLETED · PHASE2
• Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma — TERMINATED · PHASE1
• Ipilimumab and Local Radiation for Selected Solid Tumors — TERMINATED · PHASE1
• Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors — COMPLETED · PHASE1
• Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas — COMPLETED · PHASE1
• High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery — TERMINATED · PHASE2
• Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma — COMPLETED · PHASE3
• Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery — COMPLETED · PHASE1
• Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery — COMPLETED · PHASE1
• Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma — TERMINATED · PHASE1
• Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma — TERMINATED · PHASE1
• Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations — COMPLETED · PHASE2
• Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer — COMPLETED · PHASE2
• Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery — COMPLETED · PHASE2
• Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery — COMPLETED · NA
• Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations — WITHDRAWN · PHASE2
• Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma — COMPLETED · PHASE1
• Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma — TERMINATED · PHASE2
• Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic — COMPLETED · PHASE2
• Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma — COMPLETED · PHASE1
• Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery — COMPLETED · PHASE2
• Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma — COMPLETED · PHASE2
• Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery — COMPLETED · PHASE2
• Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery — COMPLETED · PHASE1
• Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma — WITHDRAWN · PHASE2
• Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer — TERMINATED · PHASE1

Refine this search